Company: DVAX
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001029142-25-000071
Chunk: 213

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 213
---
ITEM 1.             FINANCIAL STATEMENTS

Dynavax Technologies Corporation

Condensed Consolidated Balance Sheets

(In thousands, except per share amounts)

March 31,2025December 31,2024(unaudited) (Note 1) AssetsCurrent assets:Cash and cash equivalents$51,720 $95,883 Marketable securities available-for-sale609,616 617,951 Accounts receivables, net of allowance for doubtful accounts of $12,313 at March 31, 2025 and December 31, 2024, respectively54,925 45,281 Other receivables1,632 1,625 Inventories74,403 70,054 Prepaid expenses and other current assets23,674 18,147 Total current assets815,970 848,941 Property and equipment, net43,272 39,001 Operating lease right-of-use assets20,869 21,608 Goodwill2,027 1,946 Other assets, net of allowance for doubtful accounts of $10,970 at March 31, 202563,790 74,760 Total assets$945,928 $986,256 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$4,330 $9,061 Accrued research and development5,654 4,310 Accrued liabilities54,292 61,066 Other current liabilities4,103 4,197 Total current liabilities68,379 78,634 Convertible Notes, net of debt discount of $4,701 and $1,646 at March 31, 2025 and December 31, 2024, respectively (Note 7)260,507 223,854 Long-term portion of lease liabilities25,521 26,388 CEPI accrual long-term (Note 6)60,337 60,337 Other long-term liabilities243 244 Total liabilities414,987 389,457 Commitments and contingencies (Note 5)Stockholders’ equity:Preferred stock: $0.001 par value, 5,000 shares authorized at March 31, 2025 and December 31, 2024; zero shares outstanding at March 31, 2025 and December 31, 2024- - Common stock: $0.001 par value, 278,000 shares authorized at